Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy. | Child and Adolescent Psychiatry and Mental Health BioMed Central Research Acute atomoxetine treatment of younger and older children with ADHD A meta-analysis of tolerability and efficacy Christopher J Kratochvil 1 Denái R Milton2 Brigette S Vaughan1 and Laurence L Greenhill3 Open Access Address University of Nebraska Medical Center 985581 Nebraska Medical Center Omaha NE 68198-5581 USA 2Eli Lilly and Company Lilly Corporate Center Indianapolis IN 46285 USA and 3New York State Psychiatric Institute 1051 Riverside Drive New York NY 10032 USA Email Christopher J Kratochvil - ckratoch@unmc.edu Denái R Milton - MILTON_DENAI@LILLY.COM Brigette S Vaughan - bvaughan@unmc.edu Laurence L Greenhill - LarryLGreenhill@cs.com Corresponding author Published 15 September 2008 Received II April 2008 Child and Adolescent Psychiatry and Mental Health 2008 2 25 doi 10.1186 1753-2000-2-25 Accepted 15 September 2008 This article is available from http www.capmh.cOm content 2 1 25 2008 Kratochvil et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Atomoxetine is FDA-approved as a treatment of attention-deficit hyperactivity disorder ADHD in patients aged 6 years to adult. Among pediatric clinical trials of atomoxetine to date six with a randomized double-blind placebo-controlled design were used in this meta-analysis. The purpose of this article is to describe and compare the treatment response and tolerability of atomoxetine between younger children 6-7 years and older children 8-12 years with ADHD as reported in these six acute treatment trials. Methods Data from six clinical trials of 6-9 weeks duration were pooled yielding 280 subjects ages 6-7 years and 860 subjects ages 8-12 years with Diagnostic and Statistical Manual
